Objectives and compliance of hypolipidemic treatment: A prospective follow-up of 100 type 2 diabetic patients with dyslipidaemia;Évaluation de l'atteinte des objectifs du traitement hypolipémiant et de l'observance chez 100 patients atteints de diabète de type 2

Journal de Pharmacie Clinique

Volumn 26, Issue 2, 2007, Pages 91-100

  Lapalu, J ^a   Lahyani, A ^a   Borget, I ^a   Christin Maitre, S ^a   Duron, F ^a   Fromigue, J ^a   Bouchard, P ^a   Tilleul, P ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Afssaps; Bad compliance; Cholesterol; Diabete; Ignorance; Risk

Indexed keywords

EZETIMIBE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIETETICS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYGIENE; HYPERTRIGLYCERIDEMIA; HYPOLIPEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 34447116411     PISSN: 02911981     EISSN: None     Source Type: Journal    
DOI: 10.1684/jpc.2007.0052     Document Type: Article

References (26)

1. Afssaps. Argumentaire. Prise en charge thérapeutique du patient dyslipidémique. Mars 2005. http://agmed.sante.gouv.fr/.
2. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus : United Kingdom Prospective Diabetes Study (UKPDS : 23). BMJ 1998 ; 316 : 823-8.
3. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries ; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001 ; 22 : 554-72.
4. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994 ; 344 : 1383-9.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 ; 333 : 1301-7.
6. Avis NE, McKinlay JB, Smith KW. Is cardiovascular risk factor knowledge sufficient to influence behavior ? Am J Prev 1990 ; 6 : 137-44.
7. Bruckert E, Thomas D, Emmerich J, Blin P, Bichon, Amelineau E. Influence d'une campagne d'information sur les facteurs de risque cardio-vasculaire, Epernon ville d'étude, résultats à 5 ans. Press Med 1999 ; 28 : 517-22.
8. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines : a comparaison of EUROASPIRE I and II in nine countries. Lancet 2001 ; 357 : 995-1001.
9. Afssaps. Recommandations. Prise en charge thérapeutique du patient dyslipidémique. Mars 2005. http://agmed.sante.gouv.fr/.
10. Afssaps. Recommandations. Prise en charge des dyslipidémies. Septembre 2000. http://agmed.sante.gouv.fr/.
11. Van Wijk BL, Klungel OH, Heerdink ER, De Boer A. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication : a systematic review. Ann Pharmacother 2005 ; 39 : 319-28.
12. Berringer R, Shibley MC, Cary CC, Pugh CB, Powers PA, Rafi JA. Outcomes of a community pharmacy-based diabetes monitoring program. J Am Pharm Assoc 1999 ; 39 : 791-7.
13. Kirk JK, Poirier JE, Mattox MG, Thomas PM, Michielutte R. Compliance with national guidelines in patients with diabetes in a family practice clinic. Pharmacotherapy 2002 ; 22 : 1541-6.
14. Executive summary of the third report of the National Cholesterol Educative Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment Panel III). JAMA 2001 ; 285 : 2486-97.
15. Ferrières J, Elbaz M, Maupas E, Carrié D, Puel J. Insuffisance de la prise en charge des patients dyslipidémiques en France. Etude Odyssée. Arch Mal Coeur Vaiss 2004 ; 97 : 187-93.
16. Kennedy AG, MacLean CD, Littenberg B, Ades PA, Pinckney RG. The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care 2005 ; 28 : 1029-34.
17. Peterson AM, Takiya L, Finley R. Meta-analysis of interventions to improve drug adherence in patients with hyperlipidemia. Pharmacotherapy 2003 ; 23 : 80-7.
18. Ali F, Laurin MY, Larivière C, Tremblay D, Cloutier D. The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels. Can J Clin Pharmacol 2003 ; 10 : 101-6.
19. Barnett CW, Nykamp D, Ellington AM. Patient-Guided Counseling in the community pharmacy setting. J Am Pharm Assoc 2000 ; 40 : 765-72.
20. Weinberger M, Murray MD, Marrero DG, Brewer N, Lykens M, Harris LE, et al. Effectiveness of pharmacist care for patients with reactive airways disease : a randomized controlled trial. JAMA 2002 ; 288 : 1594-602.
21. Grant RW, Devita NG, Singer DE, Meigs JB. Improving adherence and reducing medication discrepancies in patients with diabetes. Ann Pharmacother 2003 ; 37 : 962-9.
22. McDonough RP, Doucette WR. Drug therapy management : an empirical report of drug therapy problem, pharmacist' interventions, and result of pharmacist' actions. J Am Pharm Assoc 2003 ; 43 : 511-8.
23. Rickheim PL, Weaver TW, Flader JL, Kendall DM. Assessment of group versus individual diabetes education. Diabetes Care 2002 ; 25 : 269-74.
24. Raji A, Gomes H, Beard JO, Mac Donald P, Conlin PR. A randomized trial comparing intensive and passive education with diabetes mellitus. Arch Intern Med 2002 ; 162 : 1301-4.
25. Yamada C, Johnson JA, Robertson P, Pearson G, Tsuyuki RT. Long-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events : extended follow-up of the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). Pharmacotherapy 2005 ; 25 : 110-5.
26. Clifford RM, Batty KT, Davis WA, Davis TME. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes. Diabetes Care 2005 ; 28 : 771-6.